390 related articles for article (PubMed ID: 17164586)
1. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.
Stoffel MP; Haverkamp H; Kromminga A; Lauterbach KW; Baldamus CA
Nephron Clin Pract; 2007; 105(2):c90-8. PubMed ID: 17164586
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated pure red-cell aplasia (PRCA): the Spanish experience.
Carracedo J; Madueño JA; Ramirez R; Martin-Malo A; de Francisco AL; Aljama P;
J Nephrol; 2005; 18(4):382-7. PubMed ID: 16245241
[TBL] [Abstract][Full Text] [Related]
3. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
[TBL] [Abstract][Full Text] [Related]
4. High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases.
Schönholzer C; Keusch G; Nigg L; Robert D; Wauters JP
Nephrol Dial Transplant; 2004 Aug; 19(8):2121-5. PubMed ID: 15252171
[TBL] [Abstract][Full Text] [Related]
5. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
Opatrný K
Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
[TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.
Stravitz RT; Chung H; Sterling RK; Luketic VA; Sanyal AJ; Price AS; Purrington A; Shiffman ML
Am J Gastroenterol; 2005 Jun; 100(6):1415-9. PubMed ID: 15929778
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of erythropoietin-associated pure red cell aplasia.
Carson KR; Evens AM; Bennett CL; Luminari S
Best Pract Res Clin Haematol; 2005; 18(3):467-72. PubMed ID: 15792921
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.
Wu G; Wadgymar A; Wong G; Ting R; Nathoo B; Mendelssohn D; Pandeya S; Sapir D; Tam P
Am J Kidney Dis; 2004 Aug; 44(2):264-9. PubMed ID: 15264184
[TBL] [Abstract][Full Text] [Related]
9. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
Casadevall N; Nataf J; Viron B; Kolta A; Kiladjian JJ; Martin-Dupont P; Michaud P; Papo T; Ugo V; Teyssandier I; Varet B; Mayeux P
N Engl J Med; 2002 Feb; 346(7):469-75. PubMed ID: 11844847
[TBL] [Abstract][Full Text] [Related]
10. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies.
Yang J; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Lee JS
J Nephrol; 2005; 18(1):102-5. PubMed ID: 15772931
[TBL] [Abstract][Full Text] [Related]
11. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
12. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures.
Thorpe R; Swanson SJ
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv16-22. PubMed ID: 15827053
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
14. Pure red-cell aplasia in a peritoneal dialysis patient with HCV-related cryoglobulinemia in the absence of neutralizing antierythropoietin antibodies.
Aterini S; Fusco I; Amato M
J Nephrol; 2004; 17(5):744-6. PubMed ID: 15593045
[TBL] [Abstract][Full Text] [Related]
15. Pure red cell aplasia induced by erythropoiesis-stimulating agents.
Pollock C; Johnson DW; Hörl WH; Rossert J; Casadevall N; Schellekens H; Delage R; De Francisco A; Macdougall I; Thorpe R; Toffelmire E
Clin J Am Soc Nephrol; 2008 Jan; 3(1):193-9. PubMed ID: 18178785
[TBL] [Abstract][Full Text] [Related]
16. Importance of biologic follow-ons: experience with EPO.
Casadevall N; Rossert J
Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
[TBL] [Abstract][Full Text] [Related]
17. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
Sikole A; Spasovski G; Zafirov D; Polenakovic M
Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
Milutinović S; Plavljanić E; Trkulja V
Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
[TBL] [Abstract][Full Text] [Related]
19. [Epoetin-induced pure red-cell aplasia].
Kharagjitsingh AV; Dekker FW; Vandenbroucke JP
Ned Tijdschr Geneeskd; 2004 Dec; 148(51):2550-3. PubMed ID: 15636479
[TBL] [Abstract][Full Text] [Related]
20. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
Macdougall IC
Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
